Retreatment of Irinotecan in Later Lines of Therapy for Metastatic Colorectal Cancer: A Retrospective Study

CONCLUSION: IRI2 might be a reasonable option for heavily pretreated patients with mCRC who achieved disease control with prior irinotecan therapy.PMID:34515197 | DOI:10.1159/000518041

Source: Oncology - September 13, 2021 Category: Cancer & Oncology Authors: Moon Ki Choi Yongjun Cha Ji Yeon Baek Source Type: research